Luciferase in vivo expression technology: Use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 400-407

  Hickey, Mark J ^a   Arain, Taraq M ^a   Shawar, Ribhi M ^a   Humble, Debbi J ^a   Langhorne, Michael H ^a   Morgenroth, Jenna N ^a   Stover, C Kendall ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIMYCOBACTERIAL AGENT; BCG VACCINE; ETHAMBUTOL; ISONIAZID; LUCIFERASE; OFLOXACIN; RIFALAZIL; RIFAMPICIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNIZATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECOMBINANT GENE; REPORTER GENE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030031876     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.400     Document Type: Article

References (32)

1. Andrew, P. W., and I. S. Roberts. 1993. Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents. J. Clin. Microbiol. 31:2251-2254.
2. Arain, T. Unpublished results.
3. Bermudez, L. E., and L. S. Young. 1988. Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob. Agents Chemother 32: 1149-1153.
4. Carlone, N. A., G. Acocella, A. M. Cuffini, and M. Forno-Pizzoglio. 1985. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am. Rev. Respir. Dis. 132: 1274-1277.
5. Collins, F. M. 1989. Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome Clin Microbiol. Rev. 2:360-377.
6. Cooksey, R. C., J. T. Crawford, W. R. Jacobs, Jr., and T. M. Shinnick. 1993. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. 37:1348-1352.
7. Cooksey, R. C., G. P. Morlock, M. Beggs, and J. T. Crawford. 1994. Bioluminescence method to evaluate antimicrobial agents against Mycobacterium avium Antimicrob Agents Chemother. 39:754-756.
8. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp Med. 178:2243-2247.
9. Frothingham, R., H. G. Hills, and K. H. Wilson. 1994 Extensive DNA sequence conservation throughout the Mycobacterium tuberculosis complex. J. Clin. Microbiol. 32:1639-1643.
10. Gangadharam, P. R., and M. D. Reddy. 1994 Contributions of animal and macrophage models to the understanding of host parasite interaction of Mycobacterium avium complex (MAC) disease. Res. Microbiol. 145:214-224.
11. Gonzales-Flecha, B., and B. Demple. 1994. Intracellular generation of superoxide as a by-product of Vibrio harveyi luciferase expressed in Escherichia coli. J. Bacteriol 176:2293-2299.
12. Imeada, T. 1985. Deoxyribonucleic acid relatedness among strains of Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium bovis BCG, Mycobacterium microli, and Mycobacterium africanum. Int. J. Syst. Bacteriol. 35: 147-150.
13. Jacobs, W. R., Jr., R. G. Barletta, R. Udani, J. Chan, G. Kalkut, G. Sosne, T. Kieser, G. J. Sarkis, G. F. Hatfull, and B. R. Bloom. 1993. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages Science 260:819-822
14. Ji, B., C. Truffot-Pernot, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1993. Effectiveness of rifampin, rifabutin, and rifapentine for preventative therapy of tuberculosis in mice. Am. Rev. Respir Dis. 148:1541-1546.
15. Klemens, S. P., M. S. DeStefano, and M. H. Cynamon. 1993 Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother. 37:2344-2347.
16. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 38:2245-2248.
17. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479
18. Kremer, L., A. Baulard, J. Estaquier, O. Poulain-Godefroy, and C. Locht. 1995. Green fluorescent protein as a new expression marker in mycobacteria. Mol. Microbiol. 17:913-922
19. Lee, M. H., L. Pascopella, W. R. Jacobs, Jr., and G. F. Hatfull. 1991. Site-specific integration of mycobacteriophage L5 integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl Acad Sci. USA 88:3111-3115.
20. Meighen, E. 1991 Molecular biology of bacterial luminescence. Microbiol. Rev. 55:123-142.
21. Mor, N., and L. Heifets. 1993. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob. Agents Chemother. 37:111-114.
22. Rastogi, N., V. Labrousse, K. S. Goh, and J. P. de Sousa. 1991. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother. 35:2473-2480.
23. Raviglione, M. C., D. E. J. Snider, and A. Kochi. 1995. Global epidemiology of tuberculosis - morbidity and mortality of a worldwide epidemic. JAMA 273:220-226.
24. Saito, H., H. Tomioka, K. Sato, M. Emori, T. Yamane, K. Yamashita, K. Hosoe, and T. Hidaka. 1991. In vitro antimicrobial activities of newly synthesized benzoxazinorifamycins. Antimicrob. Agents Chemother. 35:542-547.
25. Sarkis, G. J., W. R. Jacobs, Jr., and G. F. Hatfull. 1995. L5 luciferase reporter mycobacteriophages a sensitive tool for the detection and assay of live mycobacteria Mol. Microbiol. 15:1055-1067
26. Sarmientos, P., J. E. Sylvester, S. Contente, and M. Cashel. 1983 Differential stringent control of the tandem E coli ribosomal RNA promoters from the rrnA operon expressed in vivo in multicopy plasmids. Cell 32:1337-1346.
27. Simpson, W. J., and J. R. M. Hammond. 1991. The effect of detergents on firefly luciferase reactions. J. Biolumin. Chemilumin 6:97-106
28. Smee, D. F., R. A. Burger, J. Coombs, J. H. Huffman, and R. W. Sidwell. 1991. Progressive murine cytomegalovirus disease after termination of ganciclovir therapy in mice immunosuppressed by cyclophosamide treatment J. Infect. Dis. 164:958-961.
29. Stover, C. K. Unpublished results.
30. Stover, C. K., G. P. Bansal, M. S. Hanson, J. E. Burlein, S. R. Palaszynski, J. F. Young, S. Koenig, D. B. Young, A. Sadziene, and A. G. Barbour. 1992. Protective immunity elicited by recombinant BCG expressing OspA lipoprotein: a candidate lyme disease vaccine. J. Exp. Med 178:197-209
31. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper, R. G. Barletta, W. R. Jacobs, and B. R. Bloom. 1991. New use of BCG for recombinant vaccines. Nature (London) 351:456-460
32. Truffot-Pernot, C., B. Ji, and J. Grosset. 1991 Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 72: 57-64.